Patent details

Basic Information

Publication number:

EP2114157

PCT Application Number:

US2007088645

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP078698008

PCT Publication Number:

WO2008083101

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

PHOSPHORAMIDATE ALKYLATOR PRODRUG FOR THE TREATMENT OF CANCER

French Title of Invention:

PROMÉDICAMENT D'ALKYLATION DE PHOSPHORAMIDATE POUR LE TRAITEMENT DU CANCER

German Title of Invention:

PHOSPHORAMIDATALKYLATOR-PRODRUG FÜR DIE KREBSTHERAPIE

SPC Number:

Dates

Filing date:

21/12/2007

Grant date:

26/05/2021

EP Publication Date:

11/11/2009

PCT Publication Date:

10/07/2008

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

26/05/2021

EP B1 Publication Date:

26/05/2021

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

21/12/2021

Expiration date:

21/12/2027

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

19/05/2021

 

 

Name:

ImmunoGenesis, Inc.

Address:

909 Fannin St Suite 2000, Houston TX 77010, United States (US)

Inventor

1

Name:

MATTEUCCI, Mark

Address:

United States (US)

2

Name:

AMMONS, Steve

Address:

United States (US)

3

Name:

DUAN, Jian-Xin

Address:

United States (US)

4

Name:

JUNG, Donald

Address:

United States (US)

Priority

Priority Number:

871865 P

Priority Date:

26/12/2006

Priority Country:

United States (US)

Classification

IPC classification:

A61K 9/08; A61K 47/10; A61K 47/26; A61K 31/535; A61P 35/00; A61K 9/19;

Publication

European Patent Bulletin

Issue number:

202121

Publication date:

26/05/2021

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages